Clinical Trials Directory
We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people who have pancreatic cancer that can be treated with surgery. We want to know if the study drug has a benefit when it is taken by patients before their surgery who then have standard chemotherapy after their surgery.
We are doing this study to find out if an experimental drug called ASP2138 (the study drug) is a safe and effective option for people with gastroesophageal junction (GEJ) cancer or metastatic pancreatic cancer.
This study has three parts: - Screening (up to 21 days): You'll get health checks like heart tests, scans, and blood work. - Study Drug Period (28-day cycles): You'll be randomly placed in one of two groups: - One group gets AZD3632 alone. -The other gets AZD3632 with another medicine called posaconazole. You'll have regular visits for tests and questions. - After Treatment: You'll have a safety check 30 days after your last dose, then visits every 12 weeks to see how your disease is doing.
In this study, people are placed into one of two groups based on certain features found in their genes. The first group, called Cohort 1, includes people who have low‑risk genetic signs. To be in this group, a person must have a mutated IGHV gene, must not have a 17p deletion, and must not have a TP53 mutation. All three conditions must be true. People in this group will first take a medicine called acalabrutinib for two cycles. After that, they will take a combination of acalabrutinib and venetoclax, called AV, for twelve more cycles. The second group, called Cohort 2, includes people who have any high‑risk genetic signs. This may include having an unmutated IGHV gene, a 17p deletion, a TP53 mutation, or a mix of these.
We are doing this study to find out if a program called AYA STEPS has a positive benefit for young people who are treated for cancer. We want to know how well this program can help cancer survivors younger than 40 manage any physical or emotional symptoms they have after treatment, and we also want to see if the program can help them be more engaged with follow-up care.
This study includes a screening visit, a treatment period lasting 8 to 12 weeks, and a follow-up. During the screening, you will have a medical exam, and information about your health and background will be collected from your hospital records. If you qualify and choose to join, you will take Vitamin B6 once a day for 8 to 12 weeks. You and a caregiver will receive study questionnaires electronically. These will be sent within 7 days after you join the study, before you start taking Vitamin B6, and again after your follow-up visit. You will have up to 14 days to complete each set of questionnaires. There is no special visit at the end of treatment. The study ends once you finish the final set of questionnaires after taking Vitamin B6.
We are doing this study to find out whether certain immunotherapy drug combinations with and without chemotherapy given before and after surgery for mesothelioma can help prevent the tumor from coming back. The two immunotherapy drugs, durvalumab and tremelimumab, are called immune checkpoint inhibitors and are used to activate the immune system against cancer. Immune checkpoint inhibitors are now approved for mesothelioma for patients who cannot undergo surgery, but they are not approved prior to surgery. The chemotherapy drugs (cisplatin or carboplatin and pemetrexed) are standard options for the treatment of mesothelioma.